中华老年医学杂志
中華老年醫學雜誌
중화노년의학잡지
Chinese Journal of Geriatrics
2014年
2期
147-149
,共3页
急性冠状动脉综合征%肝素,低分子量%血小板聚集抑制剂
急性冠狀動脈綜閤徵%肝素,低分子量%血小闆聚集抑製劑
급성관상동맥종합정%간소,저분자량%혈소판취집억제제
Acute coronary syndrome%Heparin,low-molecular-weight%Platelet aggregation inhibitors
目的 观察替罗非班联合低分子肝素治疗急性冠状动脉(冠脉)综合征的临床治疗效果及其安全性. 方法 选取本科室2011年1月至2013年1月间收治的老年急性冠脉综合征患者138例为研究对象,随机分为观察组和对照组.其中观察组80例,在常规治疗的基础上,给予替罗非班和低分子肝素治疗；对照组58例,在常规治疗的基础上,给予低分子肝素治疗；对比分析两组患者临床治疗效果及其不良反应发生情况. 结果 观察组临床治疗总有效率显著比对照组临床治疗总有效率高,差异有统计学意义(x2 =8.589,P=0.003)；观察组24 h心绞痛发作次数、心电图ST段下降值和肌钙蛋白T峰值改善明显优于对照组相应指标,差异有统计学意义(P＜0.05).观察组血小板计数与对照组比较,差异无统计学意义(t=0.294,P=0.385).观察组不良反应发生率与对照组比较,差异无统计学意义(x2 =0.747,P=0.387). 结论 替罗非班联合低分子肝素治疗急性冠脉综合征,可提高临床治疗效果,改善患者相关临床症状和体征,安全性好,值得临床应用.
目的 觀察替囉非班聯閤低分子肝素治療急性冠狀動脈(冠脈)綜閤徵的臨床治療效果及其安全性. 方法 選取本科室2011年1月至2013年1月間收治的老年急性冠脈綜閤徵患者138例為研究對象,隨機分為觀察組和對照組.其中觀察組80例,在常規治療的基礎上,給予替囉非班和低分子肝素治療；對照組58例,在常規治療的基礎上,給予低分子肝素治療；對比分析兩組患者臨床治療效果及其不良反應髮生情況. 結果 觀察組臨床治療總有效率顯著比對照組臨床治療總有效率高,差異有統計學意義(x2 =8.589,P=0.003)；觀察組24 h心絞痛髮作次數、心電圖ST段下降值和肌鈣蛋白T峰值改善明顯優于對照組相應指標,差異有統計學意義(P＜0.05).觀察組血小闆計數與對照組比較,差異無統計學意義(t=0.294,P=0.385).觀察組不良反應髮生率與對照組比較,差異無統計學意義(x2 =0.747,P=0.387). 結論 替囉非班聯閤低分子肝素治療急性冠脈綜閤徵,可提高臨床治療效果,改善患者相關臨床癥狀和體徵,安全性好,值得臨床應用.
목적 관찰체라비반연합저분자간소치료급성관상동맥(관맥)종합정적림상치료효과급기안전성. 방법 선취본과실2011년1월지2013년1월간수치적노년급성관맥종합정환자138례위연구대상,수궤분위관찰조화대조조.기중관찰조80례,재상규치료적기출상,급여체라비반화저분자간소치료；대조조58례,재상규치료적기출상,급여저분자간소치료；대비분석량조환자림상치료효과급기불량반응발생정황. 결과 관찰조림상치료총유효솔현저비대조조림상치료총유효솔고,차이유통계학의의(x2 =8.589,P=0.003)；관찰조24 h심교통발작차수、심전도ST단하강치화기개단백T봉치개선명현우우대조조상응지표,차이유통계학의의(P＜0.05).관찰조혈소판계수여대조조비교,차이무통계학의의(t=0.294,P=0.385).관찰조불량반응발생솔여대조조비교,차이무통계학의의(x2 =0.747,P=0.387). 결론 체라비반연합저분자간소치료급성관맥종합정,가제고림상치료효과,개선환자상관림상증상화체정,안전성호,치득림상응용.
Objective To observe the efficacy and safety of tirofiban combined with lowmolecular-weight heparin in treatment of acute coronary syndrome.Methods 138 patients with acute coronary syndrome were divided into two groups(observation group and control group).In observation group,80 cases were treated with tirofiban combined with low-molecular-weight heparin on the basis of conventional therapy.In control group,58 cases were treated with low-molecularweight heparin on the basis of conventional therapy.The efficacy and safety were compared between the two groups.Results The total efficacy was higher in observation group than in control group (x2=8.589,P＜ 0.01).The improvement of 24 h anginal attacks,decrease in values of ECG ST segment and cardiac troponin T value were better in observation group than in control group(all P＜ 0.05).The blood platelet count and adverse reactions were not different between the two groups(t=0.294,x2 =0.747,both P ＞ 0.05).Conclusions Tirofiban combined with low-molecular-weight heparin is effective and safe in the treatment of acute coronary syndrome.It can increase the clinical effect,improve clinical symptoms and signs in the patients,and is worthy of clinical application.
